XSHG
688276
, Last price
Name
Changchun BCHT Biotechnology Co
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
2.36%
Rev. gr., 5y
-15.94%
Revenues
605m
-50.77%
Net income
-272m
L
CFO
231m
-43.12%
Dividend
Jun 18, 20250.169 /sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Changchun BCHT Biotechnology Co. Ltd. is a biopharmaceutical enterprise primarily focused on the research, development, production, and global commercialization of vaccines designed for human use. Its extensive product portfolio features key immunizations such as attenuated (live) herpes zoster and varicella vaccines, alongside a live, nasal, and freeze-dried influenza vaccine, and a rabies vaccine utilizing vero cell technology. This company was established in 2004 and is headquartered in Changchun, China.
Legal address
高新开发区火炬路1260号
长春市, JL 130012
CN
长春市, JL 130012
CN
Headquarters
高新开发区卓越大街138号
长春市, JL 130103
CN
长春市, JL 130103
CN
Address
1260 Huoju Road, Changchun High-tech Zone
Changchun, JL 130012
CN
Changchun, JL 130012
CN
Address
138 Zhuoyue Street, Changchun High-tech Zone
Changchun, JL 130103
CN
Changchun, JL 130103
CN
Other language
Changchun BCHT Biotechnology Co.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||